NCT02205099已完成1 期
A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 39
- 试验地点
- 1
- 主要终点
- Change from baseline in vital signs.
研究概览
简要总结
This is a single-site, randomized, double-blind, placebo-controlled, multiple dose, flexible dosage range, PK and PD study of SKL15508 as monotherapy in subjects with stable schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject or, when applicable, the subject's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
- •Participants who are nonsterile and sexually active agree to use a double-barrier method of contraception (must be used regardless of any other contraception in use) from the time of providing informed consent throughout the duration of the study and for 12 weeks after the last dose of study drug. Nonsterile males must be advised not to donate sperm and women should not donate ova throughout the duration of the study and for 12 weeks after the last dose of study drug.
- •Must be male or non-pregnant, non-lactating female subjects, 18 to 60 years of age, inclusive
- •Has a body mass index (BMI) between 18.0 and 38.0 kg/m2, inclusive
- •Has a clinical diagnosis of schizophrenia and, in the opinion of the Investigator, is able to safely be off his or her prescribed antipsychotic medications while participating in the study and has a very high likelihood of not deteriorating over a 3-week timeframe when off standard of care as outpatients during the Screening Period
- •Has been receiving a stable dose of antipsychotic medication for at least 1 month before Screening
- •Has not had an acute exacerbation of psychosis or hospitalization for the treatment of schizophrenia for at least 3 months before Screening
- •By history, has not had a marked change in smoking or tobacco/nicotine use from 30 days before Screening.
- •Must reside in a stable residence for at least 8 weeks before the Screening Visit
排除标准
- •At risk of suicide (e.g., per Columbia Suicide Severity Rating Scale [C-SSRS]) or have made a suicide attempt in the 6 months before Screening
- •Has a known sensitivity to sulfur-containing drugs or sulfates in food
- •Taking any medication known to influence coagulation, such as acetylsalicylic acid (aspirin), and including prescription, herbal remedies, vitamin supplements and over-the-counter products
- •Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal or endocrine disease or other abnormality (other than the disease being studied), which may impact the ability of the subject to participate or potentially confound the study results
- •Has a positive urine drug result for drugs of abuse (i.e., illicit, illegal or without valid prescription or medical need) at Screening or Admission
- •Has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis), or had a transfusion of any blood product within 45 days before Day 1
- •Has an abnormal (clinically significant) electrocardiogram (ECG) at Screening or unit admission day
- •Has a blood pressure and pulse rate outside the protocol defined ranges
- •Has a QT interval or PR outside of the protocol defined ranges
- •Has abnormal laboratory values that suggest a clinically significant underlying disease
- •Has a history of a primary DSM-IV axis I diagnosis other than schizophrenia
- •Has a medical condition other than schizophrenia (e.g., dementia, antisocial personality, borderline personality disorders) that can cause cognitive impairment or interfere with the performance or completion of study-defined procedures
- •Has been taking medication for a medical condition for less than 2 months even if at a stable dose or regimen
- •Currently taking lithium or any psychotropic medication that cannot be discontinued for safety reasons
研究组 & 干预措施
SKL15508 High Dose
Experimental
SKL15508 High Dose
干预措施: SKL15508 (Drug)
SKL15508 Medium Dose
Experimental
SKL15508 Medium Dose
干预措施: SKL15508 (Drug)
SKL15508 Low Dose
Experimental
SKL15508 Low Dose
干预措施: SKL15508 (Drug)
Placebo
Placebo Comparator
Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Change from baseline in vital signs.
时间窗: 10 days
Number and percent of subjects experiencing an adverse event.
时间窗: 10 days
Change from baseline in event-related potentials (ERP) following multiple oral doses of SKL15508.
时间窗: During the course of 10 days
Change from baseline in clinical laboratory assessments.
时间窗: 10 days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's DiseasePsychosis Associated With Alzheimer's DiseasePsychotic DisordersAlzheimer DiseaseNCT06540833Intra-Cellular Therapies, Inc.370
已完成
2 期
TC-5214 as add-on the Treatment of Major Depressive DisorderMajor Depressive DisorderDepressionNCT00692445Targacept Inc.574
招募中
2 期
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaNCT06651567Intra-Cellular Therapies, Inc.320
已完成
3 期
Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or DivalproexBipolar I DisorderNCT01358357Sumitomo Pharma America, Inc.965
撤回
2 期
Safety and Efficacy Study of IMM 124-E (Bovine Colostrum) for Patients With Nonalcoholic SteatohepatitisNonalcoholic SteatohepatitisNCT01466894Immuron Ltd.